All News

Findings from a phase 1 study highlight that ivosidenib tablets did not raise any new safety signals in the treatment of patients with IDH1-mutated relapsed/refractory myelodysplastic syndromes.

Investigators of the phase 1/2 Acclaim-3 trial will assess quaratusugene ozeplasmid in combination with atezolizumab as a treatment for those with extensive-stage small cell lung cancer.

Avyakta Kallam, MBBS and Julie Vose MD, MBA, review available treatment options for patients with mantle cell lymphoma.

Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.

Findings from a real-world study suggest the importance of novel agents for improving efficacy outcomes and tolerability in elderly patients with mantle cell lymphoma.

In the August Letter to Readers, Julie M. Vose, MD, MBA, discusses the recent cisplatin shortages and how this can be mitigated in the future.

Physician burnout is not just a phase, but rather a mental health issue that has made itself well-known in the medical community, with many clinicians trying to find strategies to cope with it.

Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.

Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Results from the phase 3 MOMENTUM trial support the use of momelotinib as a treatment for patients with myelofibrosis, including those with anemia or thrombocytopenia.

Cutting out radiotherapy appears to be safe while improving quality of life in patients with POLE-mutated endometrial cancer.

Treatment with immune checkpoint inhibitors does not raise any new safety signals among patients with locally advanced or metastatic penile squamous cell carcinoma in an international cohort study.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Investigators also report that disease-free survival was not associated with regional node irradiation treatment in favorable-risk, node-positive breast cancer.

The experimental agent appears tolerable in patients with newly diagnosed FLT3-mutated acute myeloid leukemia in a phase 1b trial.

Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.

The first and only dual action tablet, niraparib and abiraterone acetate, is now available for use in patients with BRCA-positive, metastatic castration-resistant prostate cancer following its approval by the FDA.

Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma.

Data from a phase 2 trial support a supplemental new drug application for isavuconazonium sulfate as a treatment for pediatric patients with invasive aspergillosis or invasive mucormycosis.

Findings from the CROSS-FIRE study may inform individualized decision-making regarding stereotactic radiosurgery for patients with small cell lung cancer, according to Chad Rusthoven, MD.

Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.

Implementation of a personalized, proactive care pathway for breast cancer survivors will be evaluated in future clinical trials, according to one of the authors of a pilot implementation study.

The FDA requires data from an additional clinical trial to support the potential approval of avasopasem for managing radiation-induced severe oral mucositis in patients with head and neck cancer.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Patients with metastatic RET fusion-positive non–small cell lung cancer may now be treated with pralsetinib, which has been granted regular approval by the FDA.

Continuing multidisciplinary discussions during the chemotherapy shortage is important for delivering the best possible care for each patient with breast cancer, according to Maryam Lustberg, MD, MPH.

Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.

The safety profile of selpercatinib in patients with RET fusion–positive non–small cell lung cancer in the phase 3 LIBRETTO-431 study is comparable with previous reports.

Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.